• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Rivaroxaban and other novel anticoagulants for stroke prevention in atrial fibrillation: time to embrace the future
Atrial fibrillation (AF) is now said to be at epidemic proportions.1 Although symptoms and heart failure are two of the main reasons that patients with AF suffer from reduced quality of life, thromboembolic complications, particularly stroke, remain the major determinant of significant morbidity and mortality.2 Importantly, the risk of thromboembolism (TE) is completely irrespective of symptoms, and hence the sad fact that people continue to present with catastrophic stroke in AF with no prior history of its detection.3 Appropriate anticoagulation is imperative to reduce the TE/stroke risk. Numerous large scale studies hav...
Source: Heart - February 18, 2013 Category: Cardiology Authors: Rajappan, K. Tags: Drugs: cardiovascular system, Epidemiology Editorials Source Type: research

Recent advances in the epidemiology, outcome, and prevention of myocardial infarction and stroke in sub-Saharan Africa
The early part of the new millennium witnessed reports of a growing burden of cardiovascular disease in Sub-Saharan Africa (SSA). However the contribution of ischemic heart disease and stroke to this increasing burden relative to that caused by hypertensive heart disease, cardiomyopathy and rheumatic heart disease was not clear. Over the last decade, data from the continent has begun to clarify this issue and suggests three main points. The burden of ischemic heart disease relative to other causes of heart disease remains low particularly in the black Africans majority. Stroke caused predominantly by hypertension is now a ...
Source: Heart - August 2, 2013 Category: Cardiology Authors: Ntsekhe, M., Damasceno, A. Tags: Drugs: cardiovascular system, Hypertension, Acute coronary syndromes, Epidemiology Global burden of cardiovascular disease Source Type: research

Why should we screen for atrial fibrillation?
Atrial fibrillation (AF) constitutes an increasing challenge to the medical community and healthcare providers. With a prevalence of almost 3% in the adult Swedish population1 and a forecasted twofold or threefold increase by 2050 in the USA, we are facing a diagnosis with epidemic proportions. Apart from increased mortality, AF also increases the risk of heart failure, hospitalisations and ischaemic stroke.2 Of these complications, ischaemic stroke gives a particularly heavy burden on patients, their family and society. Ischaemic stroke is the most common reason for permanent neurological disability in the adult Western p...
Source: Heart - December 8, 2016 Category: Cardiology Authors: Svennberg, E., Engdahl, J. Tags: Press releases, Drugs: cardiovascular system, Epidemiology Editorials Source Type: research

Biomarkers and atrial fibrillation: is it prime time yet?
Atrial fibrillation (AF) is a global epidemic with increasing burden on healthcare systems.1 AF is associated with increased risk of thromboembolic stroke, heart failure, cognitive dysfunction and mortality. In improving prognosis, the focus of management revolves around stroke prevention with clinical scores developed to identify people with increased stroke risk. The CHADS2 and CHA2DS2-VASc scores are the most commonly used scores, with the latter being better able to discriminate low-risk subjects.2 However, both the risk scores have a modest predictive value for identifying high-risk subjects for stroke with C statisti...
Source: Heart - July 3, 2014 Category: Cardiology Authors: Mahajan, R., Lau, D. H., Sanders, P. Tags: Drugs: cardiovascular system, Echocardiography, Clinical diagnostic tests, Epidemiology Editorials Source Type: research